Neunteufel W, Tatra G, Bieglmayer C
Second Department of Obstetrics and Gynecology, University of Vienna, Austria.
Gynecol Obstet Invest. 1990;29(2):154-7. doi: 10.1159/000293323.
In a prospective study, serum concentrations of squamous cell carcinoma (SCC) antigen were determined by radioimmunoassay from 74 healthy volunteers and 54 patients with cervical carcinoma who underwent irradiation therapy. 5.4% of the controls had SCC levels greater than 3.0 ng/ml, which was considered as upper limit of the normal range. 31/54 (57.4%) patients and 60% of the patients with SCC had elevated pretreatment levels. In all patients with pretreatment serum levels above 3.0 ng/ml, SCC serum levels decreased during irradiation therapy. 4/5 patients with posttreatment levels greater than 0.5 ng/ml developed recurrence or persistence of tumor, 1 patient could not be followed up. Good conformity was found between SCC antigen serum levels and therapy response. SCC antigen determinations during and after therapy provide a useful tool in detecting progression and persistence of tumor.
在一项前瞻性研究中，通过放射免疫分析法测定了74名健康志愿者和54名接受放射治疗的宫颈癌患者血清中鳞状细胞癌（SCC）抗原的浓度。5.4%的对照组SCC水平高于3.0 ng/ml，这被视为正常范围的上限。31/54（57.4%）的患者以及60%的SCC患者治疗前水平升高。在所有治疗前血清水平高于3.0 ng/ml的患者中，放射治疗期间SCC血清水平下降。治疗后水平高于0.5 ng/ml的5名患者中有4名出现肿瘤复发或持续存在，1名患者无法进行随访。发现SCC抗原血清水平与治疗反应之间具有良好的一致性。治疗期间和治疗后SCC抗原的测定为检测肿瘤进展和持续存在提供了一种有用的工具。
